JP4383869B2 - 軸索成長のｎｏｇｏのレセプターを仲介とした妨害 - Google Patents

軸索成長のｎｏｇｏのレセプターを仲介とした妨害 Download PDF

Info

Publication number
JP4383869B2
JP4383869B2 JP2003534444A JP2003534444A JP4383869B2 JP 4383869 B2 JP4383869 B2 JP 4383869B2 JP 2003534444 A JP2003534444 A JP 2003534444A JP 2003534444 A JP2003534444 A JP 2003534444A JP 4383869 B2 JP4383869 B2 JP 4383869B2
Authority
JP
Japan
Prior art keywords
polypeptide
nogo
seq
amino acids
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003534444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508165A (ja
JP2005508165A5 (https=
Inventor
スティーブン・エム・ストリットマター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2005508165A publication Critical patent/JP2005508165A/ja
Publication of JP2005508165A5 publication Critical patent/JP2005508165A5/ja
Application granted granted Critical
Publication of JP4383869B2 publication Critical patent/JP4383869B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
JP2003534444A 2001-10-06 2002-10-04 軸索成長のｎｏｇｏのレセプターを仲介とした妨害 Expired - Fee Related JP4383869B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/972,599 US7119165B2 (en) 2000-01-12 2001-10-06 Nogo receptor-mediated blockade of axonal growth
PCT/US2002/032007 WO2003031462A2 (en) 2001-10-06 2002-10-04 Nogo receptor-mediated blockade of axonal growth

Publications (3)

Publication Number Publication Date
JP2005508165A JP2005508165A (ja) 2005-03-31
JP2005508165A5 JP2005508165A5 (https=) 2006-01-05
JP4383869B2 true JP4383869B2 (ja) 2009-12-16

Family

ID=25519870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003534444A Expired - Fee Related JP4383869B2 (ja) 2001-10-06 2002-10-04 軸索成長のｎｏｇｏのレセプターを仲介とした妨害

Country Status (6)

Country Link
US (6) US7119165B2 (https=)
EP (1) EP1451337A4 (https=)
JP (1) JP4383869B2 (https=)
AU (1) AU2002334889B2 (https=)
CA (1) CA2461655A1 (https=)
WO (1) WO2003031462A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522016A (ja) * 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
DE60141409D1 (de) * 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ES2346868T3 (es) * 2002-08-10 2010-10-21 Yale University Antagonistas de receptor nogo.
US7408028B2 (en) * 2002-12-06 2008-08-05 Sinapore General Hospital Pte Ltd. Peptides, antibodies thereto, and their use in treatment of central nervous system, damage
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
CA2519227C (en) 2003-03-19 2013-12-03 Biogen Idec Ma Inc. Nogo receptor binding protein
US7541335B2 (en) * 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
EA009643B1 (ru) * 2003-04-16 2008-02-28 Йейл Юниверсити Лечение состояний, включающих амилоидные бляшки
JP2007537985A (ja) * 2003-05-15 2007-12-27 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー 免疫調節ペプチド
US20080274112A1 (en) * 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20080274077A1 (en) * 2003-12-16 2008-11-06 Children's Medical Center Corporation Method for Treating Neurological Disorders
KR20070052237A (ko) * 2004-01-30 2007-05-21 비오겐 아이덱 엠에이 아이엔씨. 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법
DK1773872T3 (en) * 2004-05-21 2017-05-08 Uab Res Found VARIABLE Lymphocyte Receptors, Associated Polypeptides and Nucleic Acids, and Uses thereof
US8486893B2 (en) * 2004-06-24 2013-07-16 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
EP1805209A4 (en) * 2004-10-01 2008-04-02 Univ Yale NOGO-A POLYPEPTIDE FRAGMENTS, VARIANT OF NOGO RECEPTOR-1 POLYPEPTIDES AND USE
WO2006056998A2 (en) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Methods of cell therapy, neurogenesis and oligodendrogenesis
WO2007008732A2 (en) * 2005-07-07 2007-01-18 Yale University Compositions and methods for suppressing axonal growth inhibition
HRP20131066T1 (hr) 2005-07-08 2013-12-06 Biogen Idec Ma Inc. Sp35 antitijela i njihova upotreba
WO2007014382A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant nogo-66 domain proteins
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US20090062199A1 (en) * 2005-08-25 2009-03-05 Biogen Idec Ma Inc. Nogo Receptor Polypeptides and Polypeptide Fragments and Uses Thereof
EP1928905B1 (de) * 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
PT1981902E (pt) 2006-01-27 2015-11-02 Biogen Ma Inc Antagonistas dos recetores nogo
US20110123535A1 (en) * 2006-05-15 2011-05-26 Biogen Idec Ma Inc. Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival
US20080027001A1 (en) * 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
EP2068866A4 (en) 2006-07-24 2010-04-07 Biogen Idec Inc METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS
EP2081429A4 (en) * 2006-08-31 2010-01-06 Biogen Idec Inc PROCESS FOR PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES
WO2009048605A1 (en) * 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
WO2009061500A1 (en) * 2007-11-08 2009-05-14 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
WO2009073141A2 (en) * 2007-11-28 2009-06-11 Strittmatter Stephen M Nogo receptor binding small molecules to promote axonal growth
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2276500A4 (en) * 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
US8580270B2 (en) 2008-09-30 2013-11-12 University Of Massachusetts Respiratory synctial virus (RSV) sequences for protein expression and vaccines
MX2012006560A (es) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
EP3369746A1 (en) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
EP0396719B1 (en) 1988-11-04 1995-07-05 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
WO2000073452A2 (en) 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
US7368531B2 (en) * 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
US6962797B2 (en) * 1998-04-15 2005-11-08 Genentech, Inc. Nucleic acids encoding PRO615
CA2331154A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides having sequence identity with acid labile subunit of insulin-like growth factor
JP2002522016A (ja) 1998-07-22 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 神経内分泌特異的タンパク質に類似したタンパク質、およびそれをコードするｃＤＮＡ
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
US6152155A (en) 1998-11-30 2000-11-28 Milligan; Lon Filter cleaning device
JP3695642B2 (ja) 1998-12-01 2005-09-14 ジェネンテック・インコーポレーテッド 血管形成及び心臓血管新生の促進又は阻害
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1263948A2 (en) 1999-03-08 2002-12-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000058473A2 (en) 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
AU3632600A (en) 1999-05-14 2000-12-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
AU6394400A (en) 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
HK1051543A1 (zh) 2000-01-12 2003-08-08 Yale University Nogo受体介导的轴突生长封锁
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
DE60141409D1 (de) 2000-10-06 2010-04-08 Biogen Idec Inc Homologe des nogo rezeptors
WO2003018631A2 (en) 2001-08-27 2003-03-06 Novartis Ag Nogo receptor homologues and their use
EP1440091A1 (en) 2001-10-22 2004-07-28 Novartis AG Nogo receptor homologues and their use
US20030113325A1 (en) * 2001-12-03 2003-06-19 Zhigang He Reducing myelin-mediated inhibition of axon regeneration
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
EP1354892A1 (en) 2002-04-19 2003-10-22 Centre National De La Recherche Scientifique (Cnrs) Peptides capable of inducing attraction of the axonal growth and their use for treating neurodegenerative diseases
US7745151B2 (en) * 2002-08-02 2010-06-29 Children's Medical Center Corporation Methods of determining binding between Nogo receptor and p75 neurotrophin receptor
ES2346868T3 (es) 2002-08-10 2010-10-21 Yale University Antagonistas de receptor nogo.
EA009643B1 (ru) * 2003-04-16 2008-02-28 Йейл Юниверсити Лечение состояний, включающих амилоидные бляшки
BRPI0413426A (pt) 2003-08-07 2006-10-17 Biogen Idec Inc antagonistas de receptor novo
US20080274112A1 (en) 2003-08-07 2008-11-06 Lee Daniel H S Nogo Receptor Antagonists
KR20070052237A (ko) 2004-01-30 2007-05-21 비오겐 아이덱 엠에이 아이엔씨. 노고 수용체 길항제를 사용한, 도파민성 신경 퇴행을수반하는 상태의 치료법
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES

Also Published As

Publication number Publication date
AU2002334889B2 (en) 2006-11-09
CA2461655A1 (en) 2003-04-17
US20130171157A1 (en) 2013-07-04
JP2005508165A (ja) 2005-03-31
EP1451337A2 (en) 2004-09-01
WO2003031462A3 (en) 2003-12-04
US7119165B2 (en) 2006-10-10
US8394929B2 (en) 2013-03-12
US20100278831A1 (en) 2010-11-04
US20170174763A1 (en) 2017-06-22
WO2003031462A2 (en) 2003-04-17
US20080219984A1 (en) 2008-09-11
US20140178392A1 (en) 2014-06-26
EP1451337A4 (en) 2005-08-17
US20020077295A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
JP4383869B2 (ja) 軸索成長のｎｏｇｏのレセプターを仲介とした妨害
JP4763207B2 (ja) 軸索成長のｎｏｇｏレセプター媒介妨害
AU2002334889A1 (en) Nogo receptor-mediated blockade of axonal growth
WO2000075184A1 (en) Modulation of protein levels using the scf complex
US20040259092A1 (en) Nogo receptor homologues and their use
JP2010506930A (ja) Ｔｌｒ１４の活性を変調するための組成物および方法
JP2001501476A (ja) 脊椎動物Ｓｍｏｏｔｈｅｎｅｄタンパク質
JPH10505508A (ja) Ｉｃａｍ−４物質及び方法
AU2006200819B2 (en) Nogo Receptor-Mediated Blockade of Axonal Growth
ZA200205403B (en) Nogo receptor-mediated blockade of axonal growth.
NZ547791A (en) Nogo receptor-mediated blockade of axonal growth
US20080241168A1 (en) Transmembrane protein amigo and uses thereof
JP2001508181A (ja) Ｉｃａｍ−４及びその診断用途
CA2589098A1 (en) Method for diagnosing and treating bone-related diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090825

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090924

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131002

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees